ASX-Dividend-Report-Banner

Suvoda Expands its Clinical Trial Offering with the Introduction of ePatient

June 27, 2024 09:00 AM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Suvoda Expands its Clinical Trial Offering with the Introduction of ePatient
Image source: Kalkine Media

With the focus on improving patient experience and reducing burden on sites 

PHILADELPHIA, June 27, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases, announced the early adopter launch of its ePatient product. This innovative solution is designed to address the complexities, inefficiencies, and frustrations patients encounter with stipend and reimbursement payments, as well as appointment management, throughout their clinical trial journey. 

ePatient is set to transform the patient experience by unifying payments, appointments, reminders, and eCOA questionnaires into a single user-friendly mobile interface with the simple, intuitive design Suvoda is known for. The application's seamless integration with Suvoda's IRT and eConsent ensures a cohesive user experience, enabling site users and patients to move effortlessly between all Suvoda products with a single sign-on. 

"By listening to the needs of our customers and leveraging our expertise in clinical trial technology, we have created a solution that not only improves the patient experience but also enhances operational efficiency for all stakeholders involved," said Elizabeth Morris, Senior Product Manager at Suvoda.  

Suvoda ePatient is expected to deliver four key benefits. 

  1. Faster Patient Payments: Streamlined patient stipend and reimbursement payments with automated triggers, reducing site burden and expediting the payment process for patients.  
  2. Improved Patient Experience: Centralized solution that improves the patient experience and engagement bringing together all necessary applications in one place and supporting multiple payment methods.  
  3. Reduced Workload on Sites and Sponsors: A single, unified platform for Suvoda ePatient, eCOA, IRT, and eConsent enables site users to seamlessly move between applications with single sign-on and a single data layer minimizing data reconciliation and decreasing the room for error.  
  4. Enhanced Privacy and Security: A robust security layer designed to ensure sensitive financial details remain confidential and inaccessible to site users.  

"Participating in a clinical trial is one of the most vulnerable periods in a patient's life," said Jagath Wanninayake, CEO of Suvoda. "We are committed to creating solutions that address the urgent moments on a patient's journey. ePatient takes us a step closer to achieving this mission." 

Suvoda will take a phased approach to rolling out ePatient starting with patient payments and followed by appointments and reminders. The application will be available on both iOS and Android devices. ePatient is available for a select group of early adopters in June 2024 with general availability expected in 2025.  

About Suvoda  
Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company's Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 1,400 trials across 85 countries. To learn more, visit suvoda.com. Follow Suvoda on LinkedIn.  

Logo - https://mma.prnasia.com/media2/1759317/4774510/Suvoda_Logo.jpg?p=medium600


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.